Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Non-cash Items (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Non-cash Items for 7 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-cash Items changed N/A to $3.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.2 million, a N/A change, with the full-year FY2024 number at $1.8 million, changed N/A from a year prior.
  • Non-cash Items was $3.2 million for Q3 2025 at Whitehawk Therapeutics, up from $459000.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $13.2 million in Q3 2021 to a low of $459000.0 in Q2 2025.
  • A 4-year average of $4.7 million and a median of $2.7 million in 2021 define the central range for Non-cash Items.
  • Biggest YoY gain for Non-cash Items was 5285.29% in 2021; the steepest drop was 13.87% in 2021.
  • Whitehawk Therapeutics' Non-cash Items stood at $10.0 million in 2021, then tumbled by 43.72% to $5.6 million in 2022, then crashed by 67.72% to $1.8 million in 2024, then soared by 78.61% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Non-cash Items are $3.2 million (Q3 2025), $459000.0 (Q2 2025), and $1.8 million (Q4 2024).